Studying Solriamfetol Modulation of TAAR-1, Dopamine, and Norepinephrine in Shift Work Disorder (SUSTAIN)

NCT06568367 · clinicaltrials.gov ↗

PHASE3

Phase

RECRUITING

Status

520

Enrollment

INDUSTRY

Sponsor class

Conditions

Excessive Sleepiness
Shift-work Disorder

Interventions

DRUG: Solriamfetol 150 mg
DRUG: Solriamfetol 300 mg
DRUG: Placebo

Sponsor

Axsome Therapeutics, Inc.